CCM
CALA

CAAS Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

CAAS Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,794
Closed -$333K – 963
2020
Q3 		$262K Buy
+3,794
New +$331K 0.01% 423

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's CALA Position: Q4 2020 in Review

CAAS Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q4 2020, closing a stake of 3,794 shares — an estimated $333K sold.

CAAS Capital Management first reported a position in CALA in Q3 2020 and held it in 1 quarter. The position peaked at $262K in Q3 2020. 105 funds tracked by Wall St. Rank hold CALA as of Q4 2020.

  • CAAS Capital Management reported no remaining Calithera Biosciences, Inc position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 3,794 Calithera Biosciences, Inc shares in Q4 2020, an estimated $333K.
  • CAAS Capital Management first reported a position in Calithera Biosciences, Inc in Q3 2020 and held it in 1 quarter.
  • CAAS Capital Management's Calithera Biosciences, Inc position peaked at $262K in Q3 2020.
  • 105 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.